Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03882845 · 2 trials · 2 indications
Post dose is measured at 24, 48 and 96 hours after dose.
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | - |
| Suspension/fasted | EXPERIMENTAL | - |
| Tablet/fasted | EXPERIMENTAL | - |
| Tablet/fed | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 3 mg PF-03882845 | DRUG | 3 mg PF-03882845, single oral dose |
| 10 mg PF-03882845 | DRUG | 10 mg PF-03882845, single oral dose |
| 30 mg PF-03882845 | DRUG | 30 mg PF-03882845, single oral dose |
| 100 mg PF-03882845 | DRUG | 100 mg PF-03882845, single oral dose |
| Spironolactone | DRUG | 100 mg spironolactone, single oral dose |
| PF-03882845 | DRUG | 25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition |
Inclusion Criteria: * Male and/or female healthy volunteers, age 18 to 55 years. Females must be of non-childbearing potential. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * Subjects who are willing and able to comply with scheduled visits, treatment pl...
PF-03882845 is an investigational small molecule being studied for use in healthy volunteers and in patients with type 2 diabetes mellitus. It is in Phase 1 clinical development for these metabolic conditions.
PF-03882845 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE.
PF-03882845 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
PF-03882845 has been studied in two completed Phase 1 clinical trials. One trial (NCT01314898) evaluated its antimineralocorticoid activity in healthy volunteers in the United States. Another trial (NCT01366287) studied its absorption from tablet versus suspension formulations and the effect of food in healthy volunteers with type 2 diabetes in Belgium.
PF-03882845 is the only name provided for this investigational drug. It is not known by any other names.